Introduction {#sec1_1}
============

Alzheimer\'s disease (AD) is a neurodegenerative disorder which does not spare the motor cortex. Experimental paradigms \[[@B1]\] and clinical studies \[[@B2],[@B3],[@B4]\] confirm the clinical observations about early involvement of motor behavior in AD patients. The main neurotransmitters implicated in the regulation of the motor cortex are acetylcholine (ACH) and glutamate as basically excitatory \[[@B5],[@B6]\] and GABA as the basic inhibitory neurotransmitter \[[@B7]\]. The cholinergic hypothesis about the central role of ACH in cognitive deterioration in AD in the light of new evidence in vitro \[[@B8],[@B9]\] and in vivo \[[@B10],[@B11]\] is enriched so as to suggest ACH as the main neurotransmitter regulating not only the cognitive but also the motor functions in AD patients already from the early stage.

Transcranial magnetic stimulation (TMS) has been widely used to assess the excitatory and inhibitory mechanisms which regulate the function of the motor cortex in AD \[[@B1],[@B12],[@B13],[@B14]\]. The effect of the cholinergic system on these inhibitory mechanisms has been extensively explored by TMS \[[@B15],[@B16]\]. A strong decrease in short-latency afferent inhibition which was reversed by acetylcholinesterase inhibitor intake was observed in various studies with AD patients \[[@B17]\]. A dominant role of ACH and a probable role of GABA as the intermediate neurotransmitter in motor control have been assumed, but a clear hypothesis concerning the underlying neuronal circuits has not yet been formed.

Among the neurophysiological parameters more often used in TMS, the silent period (SP) is considered as a direct indicator for cortical inhibition. It provides information about the underlying pathophysiological mechanisms, especially when measured in subjects taking pharmacological agents with an effect upon basic neurotransmitters \[[@B9],[@B16],[@B18]\]. The SP is defined as the interval of the cease of electromyographic activity which follows the production of a motor-evoked potential (MEP) in a muscle sustaining isometric voluntary contraction after the application of TMS in the primary motor area (M1). SP duration is the main parameter used to assess the cortical inhibition and is defined as the difference between the SP onset and the SP offset. However, the methods used to determine the onset and offset of the SP differ widely between studies. The SP onset has been defined as the onset of TMS, the MEP onset, the MEP offset, or when electromyography (EMG) drops below the volitional pre-TMS EMG level. The SP offset has been defined as the first return of any volitional EMG, the absolute return of EMG to the pre-TMS level, or when EMG no longer significantly differs from the pre-TMS EMG level \[[@B19],[@B20]\]. The evaluation of the whole SP duration is also difficult as sometimes, it can be temporarily interrupted by an electromyographic breakthrough of short duration and a low amplitude called 'late excitatory potential' (LEP), leading to a false, shorter SP. Several LEPs can scatter the SP into a lot of valleys until the final return of the full electromyographic activity. The occurrence of LEPs could be due to the activation of slow motor pathways or due to the activation of reflex pathways, but the most prominent hypothesis links them to cortical disinhibition \[[@B21]\].

Up until now, the SP has not been extensively studied in AD patients. The main reasons for this are the general problems arising with the calculation of the SP such as the considerable interindividual variation of its duration, the high degree of intraindividual asymmetry, the variable results when different examiners apply the TMS in the same subject \[[@B22]\], and the difficulty of an AD patient to collaborate.

In the present study, single-pulse TMS was applied in early AD patients before and after donepezil intake; the parameters of the SP were measured in order to explore the underlying cortical circuits.

Patients and Methods {#sec1_2}
====================

Patients {#sec2_1}
--------

Thirteen right-handed patients with AD (6 men, 7 women, mean age 72.9 ± 8.4 years) were studied. All patients were diagnosed with probable AD according to the criteria of the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer Disease and Related Disorders Association. They were in an early stage of the disease according to the Clinical Dementia Rating Scale. The Mini Mental State Examination (MMSE) was evaluated in all patients. The mean MMSE score was 23.6 ± 2.4. Patients who exhibited signs of other neurological diseases or those who were on medications with a possible effect on the cognitive function or the excitability of the nervous system were excluded. The neurological motor examination was normal. The patients were independent in the elementary activities of daily living even if some instrumental activities of daily living were impaired. All the patients underwent a brain MRI to exclude cerebral vascular lesions or any cause of reversible dementia.

All AD patients had the examination performed before the introduction of treatment with a cholinesterase inhibitor (10 mg donepezil per week once a day). The whole procedure was repeated after 2 months of treatment in all patients except one (patient 11) who did not reappear for the follow-up.

The age-matched (71.5 ± 8.4 years) control group consisted of 13 right-handed normal subjects (7 men, 6 women) with no history of neurological disease and a completely normal neurological examination.

All patients and all normal subjects were able to collaborate well during the electrophysiological procedure. They gave informed consent for the study which was approved by the local ethics committee.

Methods {#sec2_2}
-------

The patients and normal subjects were seated comfortably on a chair in a quiet examination room. The EMG of the right abductor digiti minimi was recorded in a Nicolet Viking IV IES 405-1 EMG machine to assess the response to TMS.

TMS was used in accordance with the consensus guidelines \[[@B23]\]. It was applied by a Magstim 200 stimulator (Magstim Ltd., Whitland, UK) through a 9-cm diameter circular coil, located at the vertex area of the scalp. The center of the coil was measured on the line between the nasion and the union point for each patient to ensure the reproducibility of the procedure from the first session to the second one 2 months later. The circulating current was turning clockwise in order to elicit a response in the target muscle. The subjects were asked to perform a slight isometric voluntary contraction of the right abductor digiti minimi (around 10% of the maximum voluntary muscle contraction) during TMS, with an auditory feedback. This active cortical motor threshold, defined as the minimal intensity of cortical stimulation which produces MEPs of approximately 200 μV in 50% of consecutive trials during isometric contraction of the tested muscle, at about 20% of maximum voluntary contraction, was determined by lowering the stimulator output gradually from 60% of the maximal output. Once the active motor threshold (aMT) was determined, the intensity of the output of the magnetic stimulator was pushed to 150% of the threshold. The patients were asked to perform a voluntary contraction of the target muscle of about 50% of the maximal voluntary contraction assessed by amplitude of the EMG response. The base time of the recordings was 500 ms.

We have chosen to measure the SP 'valley' defining the onset of the SP by the MEP offset and the offset of the SP by the return of the electromyographic activity in an amplitude which no longer differed from the pre-EMG level and not by the first return of any volitional EMG. The duration of the SP was analyzed as well as the presence or absence of LEPs and, when present, their latency, amplitude and duration. The results were compared and statistically analyzed between groups by using unpaired Student\'s t test.

Results {#sec1_3}
=======

The results are summarized in table [1](#T1){ref-type="table"}.

Normal Subjects {#sec2_3}
---------------

The mean ± SD aMT for normal subjects was 32.8 ± 7.7%. EMG following TMS generally showed the pattern of an MEP at a latency of around 20 ms followed by an SP of variable duration. LEPs were observed in 1/13 subjects (7%; patient L., 70 years old) with a latency of 67 ms, an amplitude of 487 µV and a duration of 111 ms. The SP duration for this subject was 229 ms. For the other normal subjects, the mean duration of the SP was 107.5 ± 42.2 ms. When the subject L. was included, the duration of the SP was 116.8 ± 52.6 ms.

AD before Treatment {#sec2_4}
-------------------

Before treatment with donepezil, the mean aMT in the 13 AD patients was 37.6 ± 3.9%. In these patients, the mean duration of the SP was 186.4 ± 88.2 ms. It was significantly increased by comparison to normal subjects (p \< 0.001).

In 9 out of 13 patients, LEPs were evident (69%), with a mean latency of 98.9 ± 41.5 ms, a mean amplitude of 815.7 ± 420.5 µV and a mean duration of 50.1 ± 22.8 ms. The SP valley was fragmented in these patients into multiple segments before the true return of full EMG activity (fig. [1](#F1){ref-type="fig"}). In the 9 patients with an LEP, the mean duration of the SP was 229.4 ± 66.3 ms, which differed significantly from the normal subjects (p \< 0.001). In the 4 patients without an LEP, the mean duration of the SP was 89.5 ± 35.7 ms (not statistically significant compared to normal subjects).

AD after Treatment {#sec2_5}
------------------

Two months after treatment with donepezil, the mean aMT in the 12 AD patients was 33.5 ± 3.5%. The mean duration of the SP was 150.5 ± 85.0 ms. There was no significant statistical difference with the normal subjects or AD patients before treatment.

LEPs occurred in 5 out of 12 patients (42%), with a mean latency of 96.8 ± 29.2 ms, a mean amplitude of 860.4 ± 225.9 µV and a mean duration of 46.6 ± 21.9 ms. There was no significant difference in latency, amplitude or duration of the LEPs between the patients before and after the treatment. In the 5 patients with an LEP, the mean duration of the SP was 221.2 ± 87.1 ms, which was not significantly different from the duration of SP in AD patients with an LEP before treatment. In the 7 patients without an LEP, the mean duration of the SP was 90.6 ± 28.6 ms, which was also not significant compared to the 4 patients without an LEP before treatment and to the normal subjects.

Discussion {#sec1_4}
==========

In our study, the duration of the whole SP valley was significantly increased in untreated AD patients compared to normal subjects. After treatment with donepezil, the duration of the SP valley decreased. A significant increase in LEP occurrence causing a fragmentation of the SP valley was also observed in AD patients compared to normal subjects, with a trend to normalize when patients were treated with donepezil. The duration, the amplitude and the latency of LEPs in AD patients did not show any significant difference before and after treatment.

Combining those results, we could hypothesize that the increased duration of the whole SP valley in AD patients before treatment could be due to the presence of multiple LEPs. The presence of an LEP itself is indicative of cortical disinhibition \[[@B21]\]. The observed return of an SP valley to normal values along with the decrease in LEP occurrence after donepezil intake suggest a cholinergic control of the neuronal circuits controlling the genesis of the LEP and the duration and shape of the SP in early AD patients.

Based on Orth and Rothwell \[[@B24]\], and later supported by more studies \[[@B19],[@B20]\], there is a strong correlation between the production of MEP and SP occurrence. It is already known that TMS primarily activates the fast-conducting pyramidal neurons leading to the genesis of MEP. However, from experiments in cats \[[@B25]\] it is also known that recurrent collaterals of these fast-conducting neurons have an inhibitory effect on slower-conducting pyramidal neurons most probably by exciting intercalated inhibitory neurons. As slow-conducting pyramidal neurons are responsible for the maintenance of tonic voluntary muscle contraction, the inhibition of those neurons is presumed to be responsible for SP occurrence.

Neuroanatomy and animal experiments indicate that in the layer I of M1 there is a very rich presence of cholinergic fibers which lessens in layers II-III \[[@B25],[@B26]\]. In layers II-III, the apical dendrites of pyramidal cells (PC) are found, which have cholinergic afferents. A strong release of ACH from cholinergic axons located in layer I can therefore stimulate the PC by acting on their muscarinic receptors. In addition, the layers II-III of the motor cortex are very rich in GABAergic neurons \[[@B27],[@B28]\]. The basket which GABAergic neurons specifically form by their axons is a connecting network with the apical dendrites of PC located there.

The results of our study show a fragmentation and an enlargement of the SP in the presence of multiple LEPs in early untreated AD patients. Along with the neurophysiological model of Orth and Rothwell \[[@B24]\] we suggest that the disturbance in ACH output in early AD leads to a decrease in excitability of the PC. Subsequently, the excitability of the intercalated inhibitory GABAergic neurons is reduced. Less inhibition is exerted by the GABAergic neurons onto the slow-conducting PC responsible for the maintenance of the voluntary isometric contraction. As a final outcome, various LEPs appear which fragment the SP valley and increase its duration.

Donepezil intake tends to normalize the shape and duration of the SP with less LEP occurrence, which strongly supports the aforementioned hypothesis. The observation that in normal subjects LEPs are extremely rare is also in favor of our hypothesis of the central role of ACH in the regulation of the pathways controlling the corticospinal outflow of the primary motor cortex.

While LEP occurrence appears to be strongly influenced by the cholinergic system, the mean latency, duration and amplitude of LEPs does not differ in all 3 groups, suggesting a noncholinergic mechanism which determines those parameters. Moreover, ACH cannot completely inhibit LEP occurrence in all AD patients. In the cases where LEPs persist despite treatment, the SP has a similar duration to that of the untreated AD patients. Maybe this could be due to a lack of therapeutic efficacy of donepezil. However, the correlation between the clinical responsiveness to donepezil and LEP occurrence was not studied here. Also, the significance of the LEP occurrence in one normal subject is not clear. Further studies are needed to examine the utility of LEPs as potential biomarkers.
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Comparison of results between groups

                                   LEP   SP duration, ms   LEP duration, ms   LEP amplitude, μV   LEP latency, ms   SP duration if LEP is present, ms   SP duration if LEP is absent, ms
  -------------------------------- ----- ----------------- ------------------ ------------------- ----------------- ----------------------------------- ----------------------------------
  *Normal subjects*                                                                                                                                     
  1                                no    125                                                                                                            125
  2                                no    132                                                                                                            132
  3                                no    58                                                                                                             58
  4                                no    122                                                                                                            122
  5                                no    187                                                                                                            187
  6                                no    89                                                                                                             89
  7                                yes   229               111                487                 67                229                                 
  8                                no    47                                                                                                             47
  9                                no    71                                                                                                             71
  10                               no    145                                                                                                            145
  11                               no    136                                                                                                            136
  12                               no    116                                                                                                            116
  13                               no    62                                                                                                             62
  Mean                                   116.8             111                487                 67                229                                 107.5
  SD                                     52.6                                                                                                           42.2
                                                                                                                                                        
  *AD patients before treatment*                                                                                                                        
  1                                yes   262               18                 1,100               46                262                                 
  2                                no    45                                                                                                             45
  3                                yes   182               27                 798                 112               182                                 
  4                                no    86                                                                                                             86
  5                                yes   162               32                 812                 98                162                                 
  6                                yes   176               42                 625                 61                176                                 
  7                                yes   364               55                 563                 181               364                                 
  8                                yes   173               86                 650                 62                173                                 
  9                                no    95                                                                                                             95
  10                               yes   238               74                 1,800               94                238                                 
  11                               yes   223               68                 625                 102               223                                 
  12                               yes   285               49                 368                 134               285                                 
  13                               no    132                                                                                                            132
  Mean                                   186.4             50.1               815.7               98.9              229.4                               89.5
  SD                                     88.2              22.8               420.5               41.5              66.3                                35.7
                                                                                                                                                        
  *AD patients after treatment*                                                                                                                         
  1                                yes   274               52                 662                 137               274                                 
  2                                no    112                                                                                                            112
  3                                yes   139               23                 854                 73                139                                 
  4                                no    140                                                                                                            140
  5                                yes   261               36                 614                 102               261                                 
  6                                no    54                                                                                                             54
  7                                yes   214               41                 1,120               64                214                                 
  8                                no    68                                                                                                             68
  9                                yes   284               81                 1,052               108               284                                 
  10                               no    94                                                                                                             94
  12                               no    86                                                                                                             86
  13                               no    80                                                                                                             80
  Mean                                   150.5             46.6               860.4               96.8              221.2                               90.6
  SD                                     85.0              21.9               225.9               29.2              87.1                                28.6
